Applies to the following strength(s): 10 mg ; 20 mg ; 10 mg/10 mL
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Anesthesia
Initial dose: 0.08 to 0.1 mg/kg. Maintenance dose during prolonged surgical procedures: 0.01 to 0.015 mg/kg 25 to 40 minutes later, then as frequently as every 12 to 15 minutes.
Continuous infusion: Initiate with an intubating dose of 80 to 100 mcg/kg followed 20 to 40 minutes later with 0.8 to 1.2 mcg/kg/minute.
Renal Dose Adjustments
Vecuronium is well tolerated without clinically significant prolongation of neuromuscular blocking effect in patients with renal failure who have been optimally prepared for surgery by dialysis.
Liver Dose Adjustments
Vecuronium is not recommended for use in patients with hepatic disease/failure.
This drug should be administered by or under the supervision of experienced clinicians familiar with the use of neuromuscular blocking agents (NMBAs). Dosage must be individualized in each case. The dosage information provided is derived from studies based upon units of drug per unit of body weight and is intended to serve as a guide only, especially regarding enhancement of neuromuscular blockade of vecuronium by volatile anesthetics and by prior use of succinylcholine.
To obtain maximum clinical benefits of vecuronium and to minimize the possibility of overdosage, the monitoring of muscle twitch response to peripheral nerve stimulation is advised.
Severe anaphylactic reactions to vecuronium, have been reported. These reactions have in some cases been life-threatening and fatal. Due to the potential severity of these reactions, the necessary precautions, such as the immediate availability of appropriate emergency treatment, should be taken. Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other NMBAs since cross-sensitivity between NMBAs has been reported.
Safety and effectiveness have not been established in pediatric patients less than 7 weeks of age.
Vecuronium is well tolerated without clinically significant prolongation of neuromuscular blocking effect in patients with renal failure who have been optimally prepared for surgery by dialysis. Under emergency conditions in anephric patients some prolongation of neuromuscular blockade may occur; therefore, if anephric patients cannot be prepared for non-elective surgery, a lower initial dose of vecuronium should be considered.